Hou et al. demonstrated in vivo and in vitro that DHM counteracts inflammation-induced insulin resistance via the PLC–CaMKK–AMPK signaling pathway and identified PLC as a potential DHM target in the mitigation of insulin resistance (Hou et al., 2021). The gene discussed is HSPG2; the disease is Insulin resistance.